• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

    4/1/25 7:00:18 AM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email

    PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.

    On January 6, 2025, Predictive Oncology announced that it has entered into an agreement to merge with Renovaro, Inc. On March 3, Renovaro announced that it has advanced the first tranche of financing to Predictive to initiate the integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. The companies continue to work towards the completion of due diligence and the finalization of a definitive merger agreement.

    Q4 2024 and Recent Highlights:

    • Announced an agreement to merge with Renovaro, Inc., and announced the receipt of the first tranche of financing from Renovaro to initiate the integration of AI/ML platform technologies, core laboratory capabilities, and business development functions in Europe and the United States.
      • Companies anticipate the signing of a definitive merger agreement imminently following the successful completion of due diligence.
    • Completed the sale of assets related to its wholly owned subsidiary, Skyline Medical Inc., to DeRoyal Industries, a global manufacturer and supplier of medical products.
      • Transaction sharpens Predictive's focus on its core AI/ML capabilities and significantly reduces the Company's ongoing expense run rate.
    • Announced that, using publicly available datasets on drugs that have either been abandoned or discontinued by large pharmaceutical companies, Predictive has developed a registry of promising candidates that can potentially be repurposed for additional or alternative indications.
    • Partnered with Switzerland-based Tecan Group Ltd. to expand high-throughput drug screening to include human tumor spheroids using automated imaging and 3D analysis.
      • Positive results from an ongoing study in collaboration with Tecan were presented at the 2025 Society for Laboratory Automation and Screening (SLAS) International Conference & Exhibition, which was held January 25-29, 2025, in San Diego, CA.
    • Announced the planned European launch of its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States.
      • The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.   
    • Received more than $3.0 million in combined gross proceeds during the first three months of 2025 from the sale to DeRoyal and issuance of common stock pursuant to warrant exercises, a registered direct offering and the first tranche of financing from Renovaro.

    "During the fourth quarter and subsequent period, we took tangible steps to sharpen our focus on our core AI/ML-based drug and biomarker discovery capabilities while implementing efficiencies across the organization to maximize long-term shareholder value," stated Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology. "Of note, our pending merger with Renovaro, if completed, will create a new AI/ML drug discovery company with unique advantages in the marketplace and the potential to meaningfully improve outcomes for cancer patients through earlier diagnosis, discovery of novel diagnostic and prognostic biomarkers, and the development of tailored therapies. With Renovaro, we have a unique opportunity to bring new hope to patients suffering from a range of difficult-to-treat cancers, and we continue to work tirelessly toward the executive of a definitive merger agreement with that goal in mind."    

    FY 2024 Financial Summary:

    • Concluded the fourth quarter of 2024 with $734,673 in cash and cash equivalents, compared to $8.7 million as of December 31, 2023, and $(202,610) in Stockholder's Deficit, compared to $8.3 million of Stockholders' Equity as of December 31, 2023.
    • Basic and diluted net loss per common share from continuing operations for the year ended December 31, 2024, decreased approximately 33% to $1.99, as compared to $2.99 for the year ended December 31, 2023.

    FY 2024 Financial Results:

    • The company recorded revenue of $1,623,817 in 2024, compared to $1,627,697 in 2023. Revenues for the years ended December 31, 2024, and December 31, 2023, were primarily derived from its Eagan operating segment. The Eagan operating segment contributed $1,539,005 and $1,135,101 for the years ended December 31, 2024, and December 31, 2023, respectively, while the Pittsburgh operating segment contributed $84,812 and $492,596, respectively.
    • Cost of sales was $826,137 and $609,212 for the years ended December 31, 2024, and December 31, 2023, respectively. Cost of sales increased primarily due to costs associated with Eagan operating segment, including increased volume of STREAMWAY systems sold and increased direct labor costs.
    • General and administrative expenses decreased by $961,025 to $7,419,892 in 2024 from $8,380,917 in 2023. The decrease was primarily due to decreases in employee-related expenses, including approximately $527,000 less in severance expense and lower costs associated with lower headcount. Additional decreases included lower legal fees and investor relations. These decreases were offset by higher professional fees, including consultants supporting our management team, and audit fees.
    • Operations expenses decreased by $417,120 to $2,851,045 in 2024 compared to $3,268,165 in 2023. The decrease in operations expenses in 2024 was primarily due to lower employee-related expenses associated with lower headcount, decreased cloud computing expenses, and lower research and development expenses.
    • Sales and marketing expenses decreased by $20,926 to $1,466,213 in 2024 compared to $1,487,139 in 2023. The decrease in 2024 was primarily due to decreased staff-related expenses resulting from headcount reductions and revisions to employee sales commission structure, offset by increased severance related to the separation of a former executive.
    • Net cash used in operating activities of continuing operations was $10,974,568 in 2024, compared to $11,784,070 in 2023. Cash used in operating activities of continuing operations decreased in 2024 primarily due to lower cash operating losses, partially offset by increases in cash used in working capital. Changes in cash used in working capital included increases in accounts receivable and decreases in accounts payable, offset by a decrease in prepaid expenses and other assets. The increase in accounts receivable was primarily due to timing of sales of STREAMWAY systems near year end where payment was collected after year end.

    Forward-Looking Statements:

    Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, the risks related to the success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners, and other factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

    Investor Relations Contact:

    Michael Moyer

    LifeSci Advisors, LLC

    [email protected]

     
    PREDICTIVE ONCOLOGY INC.
    CONSOLIDATED BALANCE SHEETS
         
      December 31,

    2024
     December 31,

    2023
    ASSETS        
    Current assets:        
    Cash and cash equivalents $734,673  $8,728,660 
    Accounts receivable, net  745,566   277,641 
    Inventories  385,728   480,803 
    Prepaid expense and other assets  306,301   512,078 
    Current assets of discontinued operations  53,649   79,249 
    Total current assets  2,225,918   10,078,431 
             
    Property and equipment, net  369,470   491,214 
    Intangibles, net  210,113   241,339 
    Lease right-of-use assets  2,064,507   2,598,091 
    Other long-term assets  102,509   105,509 
    Non-current assets of discontinued operations  -   902,665 
    Total assets $4,972,517  $14,417,249 
             
    LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY        
    Current liabilities:        
    Accounts payable $1,142,919  $1,334,064 
    Note payable  -   150,408 
    Accrued expenses and other liabilities  1,407,987   1,542,948 
    Derivative liability  -   1,376 
    Contract liabilities  304,985   302,499 
    Lease liability  572,739   444,897 
    Current liabilities of discontinued operations  164,771   174,839 
    Total current liabilities  3,593,401   3,951,031 
             
    Other long-term liabilities  23,487   5,459 
    Lease liability – net of current portion  1,558,239   2,130,977 
    Non-current liabilities of discontinued operations  -   58,002 
    Total liabilities  5,175,127   6,145,469 
             
    Stockholders' (deficit) equity:        
    Preferred stock, 20,000,000 shares authorized inclusive of designated below        
    Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of December 31, 2024, and December 31, 2023  792   792 
    Common stock, $.01 par value, 200,000,000 shares authorized, 6,666,993 and 4,062,853 shares outstanding as of December 31, 2024, and December 31, 2023, respectively  66,670   40,629 
    Additional paid-in capital  180,156,199   175,992,242 
    Accumulated deficit  (180,426,271)  (167,761,883)
    Total stockholders' (deficit) equity  (202,610)  8,271,780 
             
    Total liabilities and stockholders' (deficit) equity $4,972,517  $14,417,249 



    PREDICTIVE ONCOLOGY INC.
    CONSOLIDATED STATEMENTS OF NET LOSS
            
     Year Ended December 31,
      2024   2023 
    Revenue$1,623,817  $1,627,697 
    Cost of sales 826,137   609,212 
    Gross profit 797,680   1,018,485 
            
    Operating expenses:       
    General and administrative expense 7,419,892   8,380,917 
    Operations expense 2,851,045   3,268,165 
    Sales and marketing expense 1,466,213   1,487,139 
    Total operating expenses 11,737,150   13,136,221 
    Total operating (loss) (10,939,470)  (12,117,736)
    Other income 89,367   152,685 
    Other expense (11,478)  (64,967)
    Gain on derivative instruments 1,376   12,457 
    Loss from continuing operations (10,860,205)  (12,017,561)
    Loss from discontinued operations (1,804,183)  (1,966,406)
    Net (loss)$(12,664,388) $(13,983,967)
            
    Loss per common share, basic and diluted:       
    Loss from continuing operations (1.99)  (2.99)
    Loss from discontinued operations (0.33)  (0.49)
    Net (loss) per common share, basic and diluted$(2.32) $(3.48)
            
    Weighted average shares used in computation – basic and diluted 5,453,632   4,014,848 
            

    This press release was published by a CLEAR® Verified individual.



    Primary Logo

    Get the next $POAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • St. Clair Gregory Sr was granted 3,268 shares, increasing direct ownership by 17% to 22,534 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:48 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Hawryluk Matthew was granted 2,368 shares, increasing direct ownership by 33% to 9,488 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:26 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Rao Veena was granted 3,268 shares, increasing direct ownership by 56% to 9,117 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:19 PM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    SEC Filings

    See more
    • Predictive Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Predictive Oncology Inc. (0001446159) (Filer)

      6/11/25 4:06:13 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Predictive Oncology Inc.

      8-K - Predictive Oncology Inc. (0001446159) (Filer)

      6/6/25 4:31:09 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form 424B5 filed by Predictive Oncology Inc.

      424B5 - Predictive Oncology Inc. (0001446159) (Filer)

      6/2/25 4:16:45 PM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

      H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      8/19/24 6:55:24 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

      HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

      6/30/21 6:22:58 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

      Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      2/1/21 10:17:27 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Court Denies Renovaro Motion for an Expedited Trial in July

      PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB's request for an expedited, two-day trial in July. The Court reached this decision citing RENB's delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The Court has scheduled trial for November 12-13, 2025. POAI looks forward to its day in Court. About Predictive On

      5/27/25 8:35:13 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

      LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t

      5/22/25 3:12:39 PM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

      LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t

      5/22/25 11:05:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $POAI
    Leadership Updates

    Live Leadership Updates

    See more
    • AIRNA Appoints Matthew Hawryluk as Chief Business Officer

      AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

      1/30/25 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Renovaro Issues Shareholder Letter and Provides Corporate Update

      Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

      1/7/25 9:15:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

      EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas

      6/27/23 8:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

      SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

      2/11/22 7:50:59 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

      3/1/21 6:23:16 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Financials

    Live finance-specific insights

    See more
    • Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

      PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

      11/13/24 7:00:21 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

      PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

      8/14/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

      PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas

      8/7/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care